Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml
Synlett 2017; 28(08): 986-988
DOI: 10.1055/s-0036-1588691
DOI: 10.1055/s-0036-1588691
letter
Solid-Phase Synthesis of a Special Phosphorylated Peptide as a Biomarker for LC–MS/MS Detection for OPNA Exposure
Further Information
Publication History
Received: 23 October 2016
Accepted after revision: 13 December 2016
Publication Date:
01 March 2017 (online)
![](https://www.thieme-connect.de/media/synlett/201708/lookinside/thumbnails/st-2016-w0710-l_10-1055_s-0036-1588691-1.jpg)
Abstract
A synthesis of d 5-VX adducted nonapeptide via solid-phase approach has been developed. The d 5-VX peptide could be used as the isotope-labeled internal standard for LC–MS/MS detecting the BuChE-OPNA biomarkers. The Kaiser test was utilized to ensure the right connections of all of the amino acids. This method offers an access to the synthesis and detection of other phosphorylated nonapeptides.
Supporting Information
- Supporting information for this article is available online at http://dx.doi.org/10.1055/s-0036-1588691.
- Supporting Information
-
References
- 1a John H, Worek F. Anal. Bioanal. Chem. 2008; 391: 97
- 1b Fidder A, Hulst AG, Noort D, de Ruiter R, van der Schans MJ, Benschop HP, Langenberg JP. Chem. Res. Toxicol. 2002; 15: 582
- 2a Morita H, Yanagisawa N, Nakajima T, Shimizu M, Hirabayashi H, Okudera H, Nohara M, Midorikawa Y, Mimura S. Lancet 1995; 346: 290
- 2b Nakajima T, Ohta S, Morita H, Midorikawa Y, Mimura S, Yanagisawa N. J. Epidemiol. 1998; 8: 33
- 2c Suzuki T, Morita H, Ono K, Maekawa K, Nagai R, Yazaki Y. Lancet 1995; 345: 980
- 3a Shih ML, Smith JR, McMonagle JD, Dolzine TW, Gresham VC. Biol. Mass Spectrom. 1991; 20: 717
- 3b Black RM, Clarke RJ, Read RW, Reid MT. J. J. Chromatogr. A 1994; 662: 301
- 3c Tørnes JA. Rapid. Commun. Mass Spectrom. 1996; 10: 878
- 3d Black RM, Read RW. J. Chromatogr. A 1997; 759: 79
- 3e Black RM, Read RW. J. Chromatogr. A 1998; 794: 233
- 3f Noort D, Hulst AG, Platenburg DH. J. M, Polhuijs M, Benschop HP. Arch. Toxicol. 1998; 72: 671
- 4 Riches J, Morton I, Read RW, Black RM. J. Chromatogr. B 2005; 816: 251
- 5a Bao Y, Liu Q, Chen J, Lin Y, Wu B, Xie J. J. Chromatogr. A 2012; 1229: 164
- 5b Noort D, Benschop HP, Black RM. Toxicol. Appl. Pharmacol. 2002; 184: 116
- 6 Abney Carter W, Knaack LS. J, Ali IA. A, Johnson CR. Chem. Res. Toxicol. 2013; 26: 775
- 7a Knaack SJ, Zhou Y, Abney WC, Jacob TJ, Prezioso MS, Hardy K, Lemire WS, Thomas J, Johnson CR. Anal. Chem. 2012; 84: 9470
- 7b Carter DM, Crow SB, Pantazides GB, Watson MC, Thomas DJ, Blake TA, Johnson CR. Anal. Chem. 2013; 85: 11106
- 7c Sporty LS. J, Lemire WS, Jakubowski ME, Renner AJ, Evans AR, Williams FR, Schmidt GJ, van der Schans JM, Noort D, Johnson CR. Anal. Chem. 2010; 82: 6593
- 8a He Z.-J, Wang Y.-M, Tang C.-C. Phosphorus, Sulfur Silicon Relat. Elem. 1997; 127: 59
- 8b Bennet AJ, Kovach I, Bibbs JA. J. Am. Chem. Soc. 1989; 111: 6224
- 10 MacDonald M, Lanier M, Cashman J. Synlett 2010; 1951
- 11 The target compound d 5-VX adducted nonapeptide was synthesized via the solid-phase peptide synthesis manually from C-terminal to N-terminal to enhance the coupling efficiency. The peptides were synthesized using Fmoc chemistry on a Fmoc-Ser (t-Bu)-Wang resin and HBTU/DIPEA activation. Piperidine–DMF (25%) was used to deprotect the Fmoc group. The rest of the amino acid residues were induced onto the resin in sequence by HBTU/DIPEA activation. The Kaiser test was used to ensure the connection with right amino acid residue upon every step. After this point, cleavage from the resin was achieved by treating the peptide resin with the solution containing 68.5% TFA, 10% 1,2-ethanedithiol, 10% thioanisole, 5% phenol, 3.5% double-distilled water, and 1% triisopropylsilane for 3 h at r.t. The crude product of the phosphorylated peptide which could be precipitated by anhydrous Et2O was further purified by reversed-phase HPLC on a C18 column (0.05% TFA–water–2% MeCN). Peptide purity was>90% by analysis of HPLC-DAD. It was also verified by NMR and high-resolution MS. HRMS (ESI+): m/z found for C36H51D5PN9O16: 907.3968. 1H NMR (599.7 MHz, D2O): δ =1.28 (t, J = 7.4 Hz, 9 H), 1.47 (d, 2 J H–C–P = 17.6 Hz, 3 H), 1.80–2.11 (m, 6 H), 2.37 (t, J = 7.1 Hz, 2 H), 3.12 (m, 3 H), 3.75–3.88 (m, 6 H), 4.20–4.35 (m, 9 H), 4.55 (s, 1 H), 7.18 (d, J = 7.2 Hz, 2 H), 7.26–7.31 (m, 3 H). 13C{1H} NMR (150.8 MHz, D2O): δ = 177.1, 175.0, 174.7, 174.6, 173.5, 173.3, 170.9, 170.7, 169.8, 169.6, 133.6, 129.3, 129.1, 128.0, 64.2, 64.1, 61.2, 61.1, 55.1, 54.4, 53.45, 53.40, 53.35, 53.1, 49.9, 49.5, 49.4, 42.2, 36.7, 30.0, 26.1, 16.7, 16,4, 9.4, 8.5. 31P{1H} NMR (242.8 MHz, D2O): δ = 35.9.